Tumor Metabolic Dependency and Target Validation
Four things often reported as one
| Term | Definition | Evidence required |
|---|---|---|
| Expression | The enzyme is present, often higher in tumour than normal | Transcript or protein, with a reference tissue |
| Sensitivity | Inhibiting it reduces viability | Dose–response, one culture condition |
| Dependency | The cell requires the activity to grow or survive | Genetic and pharmacological concordance; rescue |
| Target | Inhibiting it produces a therapeutic margin | Effect in vivo at achievable exposure, with normal-tissue tolerance |
Most published "metabolic targets" sit at row two. The distance from row two to row four is where programmes fail, and each row requires a different experiment.
Gate 1 — Is this the right node?
| Question | Why it decides the outcome |
|---|---|
| Which isoform? | Isoform redundancy buffers single-enzyme inhibition; pan-isoform tools obscure it |
| Which compartment? | Cytosolic and mitochondrial pools of the same metabolite are separate |
| Is the enzyme a control point? | Control is distributed; the enzyme with the largest expression change is often not the one that sets flux |
| Is there a bypass? | Substrate-level alternatives (e.g. exogenous serine, salvage nucleotides) can make the node irrelevant |
Important distinction. High expression is a hypothesis about a node, not evidence that the node controls flux. Control analysis in central metabolism repeatedly shows that no single step holds most of the control, which is why an enzyme can be 90% inhibited with a small flux change.
Caveat on isoform coverage. A tool compound that inhibits one isoform of a redundant pair will look inactive, and the conclusion "this pathway is dispensable" will be wrong. The genetic experiment — knocking out both — is what distinguishes redundancy from dispensability.
Gate 2 — Does inhibition change flux, not just the pool?
A metabolite pool is the integral of production minus consumption. It can fall because production fell, or because consumption rose.
| Measurement | What it supports | What it does not |
|---|---|---|
| Steady-state pool | The concentration changed | Direction of the flux change |
| Labelled precursor incorporation | Route and rate of entry | Absolute flux without a model |
| Product secretion rate | Net pathway output | Which step changed |
| Rescue with the downstream product | The pathway, not the enzyme, is required | That the enzyme is the target |
| Rescue with the upstream substrate | The block is at or before that step | Where exactly |
Readout note. For a drug programme the useful measurement is the product, not the substrate. Inhibiting a biosynthetic enzyme raises its substrate and lowers its product; only the product change maps onto the biological consequence. A programme that reports substrate accumulation alone has shown target engagement, not pathway inhibition.
Gate 3 — Does the tumour depend on it where the tumour lives?
Dependency is a property of the environment as much as of the genome.
| Environment | What changes | Why it matters |
|---|---|---|
| Culture medium | Glucose, glutamine, serine, lipids at supraphysiological concentrations | Removes the restriction that creates dependency |
| Two-dimensional versus spheroid | Nutrient gradients, oxygen, proliferation gradient | Averages over heterogeneity |
| Xenograft | Mouse plasma composition, host metabolism, delivery | The relevant comparison for a drug |
| Genetic model | Intact immune system, native stroma | Dependency may be immune-mediated |
Important distinction. Many metabolic dependencies are medium artefacts in the specific sense that they exist only when the relevant nutrient is limiting. Serine synthesis, for example, is dispensable in standard medium that contains serine and becomes essential when serine is withdrawn. Both statements are true; only one is relevant to a patient, and which one depends on the tumour's vascular supply — which is the measurement nobody makes.
Gate 4 — Is there a window?
| Normal tissue | Why it is at risk | How it limits the target |
|---|---|---|
| Bone marrow | High proliferative flux; nucleotide and one-carbon demand | Antifolates and nucleotide inhibitors |
| Intestinal epithelium | Rapid turnover, high glutamine use | Glutaminase inhibitors |
| Activated immune cells | Glycolytic and glutamine-dependent on activation | Immunosuppression as on-target toxicity |
| Liver | Central carbon and nitrogen hub | Hepatotoxicity at effective exposure |
Important distinction. The most attractive metabolic targets are those required by the tumour and not required by the adult organism. Nucleotide salvage versus de novo synthesis is the clearest example: adults can salvage, many tumours lose the salvage route, so the de novo pathway becomes tumour-selective. This is a stronger argument than differential expression, because it is a difference in requirement rather than in abundance.
Genotype-selected vulnerability
The strongest version of a metabolic target is one where the tumour's genotype creates the dependency, because the genotype is also the biomarker.
| Lesion | Consequence | Therapeutic logic |
|---|---|---|
| MTAP deletion (with CDKN2A) | MTA accumulates; MAT2A and PRMT5 axis stressed | MAT2A inhibition collapses the axis further |
| Somatic SDH or FH loss | Oncometabolite accumulation | Downstream dependencies, not the enzyme itself |
| Isocitrate dehydrogenase mutation | 2-HG production | The mutant enzyme, not the pathway |
| VHL loss | Constitutive HIF signalling | Context-dependent; usually not a metabolic node |
Caveat on the biomarker. Genotype-selected programmes require the biomarker assay to be validated in the same tissue and platform as the trial. A deletion call from a targeted panel and a call from whole-genome sequencing can disagree at the boundary, and the disagreement falls exactly on the patients who would be enrolled.
The validation sequence, in the order that saves money
- Isoform and compartment resolved genetically — knockout both isoforms, or use compartment-specific perturbation.
- Flux, not pool — product secretion or labelled incorporation.
- Rescue with the product — establishes that the pathway, not a downstream side effect, is required.
- Two culture conditions — permissive and restricted medium; report both.
- In vivo at achievable exposure — with plasma concentration measured, not assumed.
- Normal-tissue tolerance — at least one proliferating normal tissue.
Steps 1 and 3 are cheap and eliminate most candidates. Step 6 is expensive and is the one most often deferred to a point where it cannot change the decision.
Failures that recur
- • Sensitivity called dependency. One cell line, one medium, one compound.
- • Compound-only evidence. No genetic arm, so off-target effects are indistinguishable.
- • Rescue with a downstream metabolite that also feeds other pathways. Succinate, pyruvate and aspartate all do this.
- • Supraphysiological inhibitor concentrations used to define the phenotype, then a nanomolar compound advanced.
- • Dependency measured in medium that contains the nutrient in question.
- • Window asserted from expression data. Expression is not requirement.
Where this connects
- • Glucose, lipid, amino acid and mitochondrial pillars supply the node-level mechanisms and the flux rules this gate sequence assumes.
- • Disease pillar supplies the host-state frame: a dependency measured in a lean, young xenograft host may not exist in the metabolic state of the patients who have the disease.
- • Synthetic lethality — the genetic-interaction logic behind the genotype-selected row — is treated in the companion articles on metabolic synthetic lethality and on designing the screen.
Scientific interpretation and experimental design
- • Expression, sensitivity, dependency and target are four different claims.
- • Resolve isoforms and compartments. Redundancy is the default.
- • Measure the product. Substrate accumulation is engagement, not inhibition.
- • Report the medium. Dependency is often a property of the medium.
- • Genetic and pharmacological arms together. Neither alone excludes off-target effects.
- • Prefer requirement differences to abundance differences. Salvage loss beats overexpression.
- • Measure exposure in vivo. Achievable concentration is part of the claim.
Selected references for further reading
- • Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery. 2011;10:671–684.
- • Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657–669.
- • Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–1218.
- • Mavrakis KJ, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208–1213.
- • Sullivan LB, Gui DY, Vander Heiden MG. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nature Reviews Cancer. 2016;16:680–693.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »